Cytosorbents

Cytosorbents EBIT per Share

The EBIT per Share of Cytosorbents (CTSO) as of Oct 25, 2026 is -1.91 USD. In the previous year, EBIT per Share was -7.68 USD — a change of -75.17% (higher).

EBIT per Share

-1.91USD

YoY

-75.17%

Last updated:

EBIT per Share of Cytosorbents is 2025 -1.91 USD. EBIT per Share of Cytosorbents was 2024 -7.68 USD. It decreases by -75.17% higher compared to the previous year.

The Cytosorbents EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-14.31 USD
Jan 1, 2024
-7.68 USD
Jan 1, 2025
-1.91 USD
Jan 1, 2026 (e)
-8.00 USD
Jan 1, 2027 (e)
-9.70 USD
Jan 1, 2028 (e)
-10.63 USD
Jan 1, 2029 (e)
-11.21 USD
Jan 1, 2030 (e)
-27.41 USD
The Cytosorbents EBIT per Share history
YEAREBIT per ShareYoY
est-27.41USD+144.61%
est-11.21USD+5.41%
est-10.63USD+9.54%
est-9.70USD+21.24%
est-8.00USD+319.82%
-1.91USD-75.17%
-7.68USD-46.33%
-14.31USD-1.32%
-14.50USD+38.59%
-10.46USD+109.83%
-4.99USD-56.16%
-11.37USD+10.93%
-10.25USD+49.80%
-6.84USD-27.42%
-9.43USD+23.67%
-7.63USD+27.77%
-5.97USD-32.77%
-8.88USD+2,167.76%
-0.39USD-96.80%
-12.25USD+15.44%
-10.61USD+1,172.84%
-0.83USD-70.12%
-2.79USD-8.86%
-3.06USD-95.02%
-61.50USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytosorbents Stock analysis

What does Cytosorbents do? Cytosorbents Corp is a US-American company specialized in the development of medical technologies for the treatment of life-threatening diseases and injuries. It was founded in 1997 by Dr. Phillip Chan. Originally, Cytosorbents specialized in the development of therapeutics for cancer therapy. After several development phases and a realignment of the company, they eventually focused on developing medical products for intensive care medicine. The business model of Cytosorbents is based on the development and marketing of blood purification systems that remove harmful substances and toxins from the blood. This can treat life-threatening diseases and complications such as sepsis, organ failure, or severe burns. An important product of Cytosorbents is the Cytosorb system, which consists of an extracorporeal blood purification device. The system is used to attenuate disease-related inflammatory reactions and remove harmful substances from the blood. This is intended to prevent complications and improve the survival of patients. Cytosorbents offers the Cytosorb system, among other things, for use in intensive and emergency medicine. It is used, among other things, to treat sepsis, which can lead to life-threatening organ failure. It is also used to treat severe burns, to rid the blood of toxic substances and inflammatory mediators, and thus accelerate the healing process. In addition to the Cytosorb system, the company also offers other medical products such as the HemoDefend plasma exchanger. This system is used to purify blood plasma from harmful substances while retaining the beneficial components in the plasma. It is used, among other things, to treat patients in need of a blood transfusion. Cytosorbents has experienced significant expansion in recent years. The company has established subsidiaries in Europe, Asia, and the Middle East and works closely with major hospitals and medical facilities. Additionally, the company has formed several partnerships with leading medical technology companies to expand the use of its technology in other areas. In summary, Cytosorbents is an innovative company specializing in the development of medical devices for the treatment of life-threatening diseases. The company has expanded significantly in recent years and collaborates with renowned hospitals and medical facilities. In the future, Cytosorbents will continue to refine and improve its technologies to help even more patients. Cytosorbents is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytosorbents stock

EBIT per Share of Cytosorbents is -1.91 USD in 2025.

EBIT per Share of Cytosorbents changed from -7.68 USD to -1.91 USD, representing a -75.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Cytosorbents since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cytosorbents

All Key Metrics — Cytosorbents